European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
The Brighterside of News on MSN2h
Weight-loss drug Semaglutide could significantly reduce the risk of heart attacksA new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
A woman fighting for her life and battling heart failure was able to take part in an an experience her whole family will ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...
CINCINNATI ( WXIX /Gray News) - A 7-year-old is in a hospital in Ohio fighting for her life after experiencing her second heart failure. Nyla Pritchett has been at Cincinnati Children’s Hospital since ...
Hope Unlimited Ministries will have its annual fundraising event featuring Point of Grace on Thursday, Oct. 17. This event ...
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In ...
2d
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces its participation in the Annual Scientific Meeting of the Heart Failure Society of America ...
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
Root canal treatment is a common dental procedure aimed at saving damaged or infected teeth. Despite concerns about its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback